Last week’s rescheduling announcement has placed a spotlight firmly on the medical cannabis arms of North America’s largest operators.
With cannabis that is subject to a state medical license now officially downgraded to Schedule III under the US Controlled Substances Act (CSA), large North American companies with stakes in both the medical and adult-use markets will likely be re-evaluating their priorities in the US market.
While the public markets appear unsure what to make of this partial rescheduling, for the likes of Tilray, Aurora®, Organigram and Curaleaf, this will come as a welcome validation of the medical cannabis empires they’ve been building throughout Europe.
Regardless of how meaningful this regulatory landmark will be for their respective balance sheets, the European M&A wave appears to be in full swing, and April 15 alone tells you everything you need to know.
On that single day, Aurora® closed a capacity-expanding cultivation acquisition in Ontario, Tilray announced its entry into the UK’s clinical market, and Organigram completed the largest North American acquisition of a European cannabis operator since Jazz Pharmaceuticals’ takeover of GW Pharmaceuticals.
Aurora®’s international medical revenues now account for 95% of its adjusted gross profit. Curaleaf’s international business grew 63% last year. Organigram just deployed its entire BAT-backed strategic capital pool on a single European acquisition.
As the US market undergoes fundamental changes that may or may not benefit these companies in the long-run, it’s abundantly clear that the European opportunity is one they believe should be grasped by both hands.
Last month, when Business of Cannabis last examined the North American push into Europe, Tilray’s strategy appeared to be focused on breadth, building an expansive network of distribution partnerships, owned assets and pharmaceutical relationships through dozens of markets.
Earlier this month, Tilray announced the acquisition of Lyphe Group, one of the UK’s longest-established medical cannabis clinics and digital pharmacy platforms.
It has been framed publicly as the foundation of its first fully vertically integrated medical platform in the UK, combining pharmaceutical-grade cultivation with clinical care, dispensing services, and pharmaceutical distribution through CC Pharma.
According to Tilray, Lyphe has treated more than 16,000 patients to date, while Lyphe has dispensed approximately 150,000 units, giving it an immediate patient base and clinical infrastructure that would have taken years to build organically.
Neither the company nor Eezy Group, which sold the business, have made the consideration public. Given Lyphe Group’s troubled financial past, having fallen into administration in 2024 and still carrying debt, it’s likely to have been well below the headline €250m of the Organigram-Sanity Group deal.
However, what is clear is that Tilray has acquired a recognised consumer brand with an established patient base, and a ready-made supply chain through which to push its own products, and likely at minimal relative cost. Lyphe’s 16,000 patients represent an active, medically validated customer base with existing prescribing relationships.
By leveraging CC Pharma’s purchasing power and its own EU-GMP cultivation capacity, Tilray is well-positioned to redirect product supply through the Lyphe platform.
It is, in effect, the same vertically integrated model that Lyphe’s founders originally built and that ultimately collapsed under the weight of its own capital requirements. The difference is that Tilray is attempting to operate it with a multinational balance sheet rather than venture capital funding, and at a fraction of the original cost of assembly. Business of Cannabis will be publishing a deeper examination of Lyphe’s administration history and the circumstances of its sale in the coming days.
Tilray’s second UK acquisition of 2026 is a rather different proposition. Six weeks after closing its £33m purchase of BrewDog, a brand that once carried a £2 billion valuation, the company has moved quickly to stabilise brewing volumes, maintain channel service levels, and begin onboarding new distribution partners.
The company has outlined plans to expand BrewDog across the UK, Australia, and the United States, with further development targeted in the Middle East and India. A ‘brewpub of the future’ investment at one of its existing locations is planned as a testbed for the wider estate. The business is expected to be cash flow positive by 2027.
On US rescheduling, chairman and CEO of Tilray Brands Irwin D. Simon argued that Tilray’s international medical infrastructure, pharmaceutical-grade cultivation, regulatory fluency across more than 20 markets, and hundreds of thousands of patients served globally, give it a foundation that domestic US operators cannot easily replicate.
Following its US$100m at-the-market equity programme, Aurora Cannabis was sitting on CA$154m in cash, having completed its transformation from a diversified cannabis group into a focused international medical business.
On April 15, the same day Tilray announced the Lyphe acquisition, Aurora® moved to expand its EU GMP-certified cultivation capacity with the acquisition of Safari Flower Company, an Ontario-based indoor cultivator and manufacturer.
The deal, valued at $26.5m and structured primarily in shares with a $15m cash component, adds a purpose-built 59,000 square foot facility to Aurora®’s supply network, with output earmarked for its key international markets including Germany, Australia, Poland, and the UK.
During its most recent quarter, Aurora®’s international medical revenues reached $37.1m, driven primarily by medical cannabis sales in Germany and Poland, making the rationale behind its capacity expansion clear.
In light of this European opportunity, Aurora® believes supply capacity is the primary constraint on further growth. Safari gives it an incremental EU GMP-certified volume without the lead time of building new infrastructure from scratch.
Aurora® expects the acquisition to deliver positive adjusted EBITDA contributions in fiscal 2027, with incremental benefits in 2028 as the assets are optimised within its supply network.
Another critical April 15 announcement came from Organigram Global, which announced the finalisation and closure of its landmark acquisition of leading German player Sanity Group.
This deal, which represents the largest North American acquisition of a European player outside of Jazz Pharmaceuticals’ takeover of GW Pharmaceuticals in 2021, is seen by many as the first domino in the M&A wave we’re now seeing.
The upfront consideration paid on closing came to €107.3m, consisting of €78m in cash and €29.3m in share consideration, with Organigram issuing shares to both Sanity’s former shareholders and to BAT, its strategic investor.
On top of that, Sanity’s former shareholders are entitled to earnout consideration of up to a further €113.8m, dependent on Sanity’s financial performance during the twelve months to April 1, 2027, meaning the total deal value could reach €221m if performance targets are met.
A portion of the cash consideration was drawn from the Jupiter Pool, a strategic capital fund established in 2024 with BAT (British American Tobacco) funding specifically to support Organigram’s international growth ambitions. The Sanity acquisition represents the final and complete deployment of that pool.
Concurrently, BAT participated in a €40.3m private placement, and Organigram closed C$60m in senior secured credit facilities with ATB Financial. BAT’s shareholding, structured carefully to remain below the 30% common share threshold via a combination of common and non-voting convertible preferred shares, now carries a conversion rate that increases at 7.5% per annum, a mechanism that could see BAT’s effective stake drift meaningfully higher over time.
The acquisition brings a number of key elements into the Organigram stable. Sanity Group has developed a commercial footprint spanning medical cannabis, regulated recreational pilot programmes, and wellbeing products, with operations extending beyond Germany into Switzerland, the UK, Poland, and Czechia.
Its distribution and logistics capabilities, regulatory expertise, and partner network across Europe represent years of ground-level market building that would be not only costly but especially time-consuming to replicate organically.
For Organigram, which has until now been primarily a Canadian cultivator with international ambitions rather than international operations, the acquisition is genuinely transformational in scope. Sanity’s former Managing Director and Chief Investment and Strategy Officer, Max Konrad Narr, has been appointed to Organigram’s board for the duration of the earnout period.
April 15 was a striking day for the sector. Aurora® closed the Safari acquisition, Tilray announced the Lyphe deal, and Organigram completed one of the largest cannabis acquisitions in European history, all on the same date. The coincidence underscores just how compressed the current window of consolidation activity has become, with multiple operators evidently concluding simultaneously that the time to move is now.
The post Has Rescheduling Accelerated the Cannabis M&A Wave? appeared first on Business of Cannabis.
Continue reading...
With cannabis that is subject to a state medical license now officially downgraded to Schedule III under the US Controlled Substances Act (CSA), large North American companies with stakes in both the medical and adult-use markets will likely be re-evaluating their priorities in the US market.
While the public markets appear unsure what to make of this partial rescheduling, for the likes of Tilray, Aurora®, Organigram and Curaleaf, this will come as a welcome validation of the medical cannabis empires they’ve been building throughout Europe.
Regardless of how meaningful this regulatory landmark will be for their respective balance sheets, the European M&A wave appears to be in full swing, and April 15 alone tells you everything you need to know.
On that single day, Aurora® closed a capacity-expanding cultivation acquisition in Ontario, Tilray announced its entry into the UK’s clinical market, and Organigram completed the largest North American acquisition of a European cannabis operator since Jazz Pharmaceuticals’ takeover of GW Pharmaceuticals.
Aurora®’s international medical revenues now account for 95% of its adjusted gross profit. Curaleaf’s international business grew 63% last year. Organigram just deployed its entire BAT-backed strategic capital pool on a single European acquisition.
As the US market undergoes fundamental changes that may or may not benefit these companies in the long-run, it’s abundantly clear that the European opportunity is one they believe should be grasped by both hands.
Tilray
Last month, when Business of Cannabis last examined the North American push into Europe, Tilray’s strategy appeared to be focused on breadth, building an expansive network of distribution partnerships, owned assets and pharmaceutical relationships through dozens of markets.
Earlier this month, Tilray announced the acquisition of Lyphe Group, one of the UK’s longest-established medical cannabis clinics and digital pharmacy platforms.
It has been framed publicly as the foundation of its first fully vertically integrated medical platform in the UK, combining pharmaceutical-grade cultivation with clinical care, dispensing services, and pharmaceutical distribution through CC Pharma.
According to Tilray, Lyphe has treated more than 16,000 patients to date, while Lyphe has dispensed approximately 150,000 units, giving it an immediate patient base and clinical infrastructure that would have taken years to build organically.
Neither the company nor Eezy Group, which sold the business, have made the consideration public. Given Lyphe Group’s troubled financial past, having fallen into administration in 2024 and still carrying debt, it’s likely to have been well below the headline €250m of the Organigram-Sanity Group deal.
However, what is clear is that Tilray has acquired a recognised consumer brand with an established patient base, and a ready-made supply chain through which to push its own products, and likely at minimal relative cost. Lyphe’s 16,000 patients represent an active, medically validated customer base with existing prescribing relationships.
By leveraging CC Pharma’s purchasing power and its own EU-GMP cultivation capacity, Tilray is well-positioned to redirect product supply through the Lyphe platform.
It is, in effect, the same vertically integrated model that Lyphe’s founders originally built and that ultimately collapsed under the weight of its own capital requirements. The difference is that Tilray is attempting to operate it with a multinational balance sheet rather than venture capital funding, and at a fraction of the original cost of assembly. Business of Cannabis will be publishing a deeper examination of Lyphe’s administration history and the circumstances of its sale in the coming days.
Tilray’s second UK acquisition of 2026 is a rather different proposition. Six weeks after closing its £33m purchase of BrewDog, a brand that once carried a £2 billion valuation, the company has moved quickly to stabilise brewing volumes, maintain channel service levels, and begin onboarding new distribution partners.
The company has outlined plans to expand BrewDog across the UK, Australia, and the United States, with further development targeted in the Middle East and India. A ‘brewpub of the future’ investment at one of its existing locations is planned as a testbed for the wider estate. The business is expected to be cash flow positive by 2027.
On US rescheduling, chairman and CEO of Tilray Brands Irwin D. Simon argued that Tilray’s international medical infrastructure, pharmaceutical-grade cultivation, regulatory fluency across more than 20 markets, and hundreds of thousands of patients served globally, give it a foundation that domestic US operators cannot easily replicate.
Aurora® Cannabis
Following its US$100m at-the-market equity programme, Aurora Cannabis was sitting on CA$154m in cash, having completed its transformation from a diversified cannabis group into a focused international medical business.
On April 15, the same day Tilray announced the Lyphe acquisition, Aurora® moved to expand its EU GMP-certified cultivation capacity with the acquisition of Safari Flower Company, an Ontario-based indoor cultivator and manufacturer.
The deal, valued at $26.5m and structured primarily in shares with a $15m cash component, adds a purpose-built 59,000 square foot facility to Aurora®’s supply network, with output earmarked for its key international markets including Germany, Australia, Poland, and the UK.
During its most recent quarter, Aurora®’s international medical revenues reached $37.1m, driven primarily by medical cannabis sales in Germany and Poland, making the rationale behind its capacity expansion clear.
In light of this European opportunity, Aurora® believes supply capacity is the primary constraint on further growth. Safari gives it an incremental EU GMP-certified volume without the lead time of building new infrastructure from scratch.
Aurora® expects the acquisition to deliver positive adjusted EBITDA contributions in fiscal 2027, with incremental benefits in 2028 as the assets are optimised within its supply network.
READ MORE…
Has Rescheduling Accelerated the Cannabis M&A Wave?
Is a Cannabis M&A Tidal Wave on the Way?
Business Brief: Canify and MG Health Announce Merger
Organigram closes Sanity Group Acquisition
Another critical April 15 announcement came from Organigram Global, which announced the finalisation and closure of its landmark acquisition of leading German player Sanity Group.
This deal, which represents the largest North American acquisition of a European player outside of Jazz Pharmaceuticals’ takeover of GW Pharmaceuticals in 2021, is seen by many as the first domino in the M&A wave we’re now seeing.
The upfront consideration paid on closing came to €107.3m, consisting of €78m in cash and €29.3m in share consideration, with Organigram issuing shares to both Sanity’s former shareholders and to BAT, its strategic investor.
On top of that, Sanity’s former shareholders are entitled to earnout consideration of up to a further €113.8m, dependent on Sanity’s financial performance during the twelve months to April 1, 2027, meaning the total deal value could reach €221m if performance targets are met.
A portion of the cash consideration was drawn from the Jupiter Pool, a strategic capital fund established in 2024 with BAT (British American Tobacco) funding specifically to support Organigram’s international growth ambitions. The Sanity acquisition represents the final and complete deployment of that pool.
Concurrently, BAT participated in a €40.3m private placement, and Organigram closed C$60m in senior secured credit facilities with ATB Financial. BAT’s shareholding, structured carefully to remain below the 30% common share threshold via a combination of common and non-voting convertible preferred shares, now carries a conversion rate that increases at 7.5% per annum, a mechanism that could see BAT’s effective stake drift meaningfully higher over time.
The acquisition brings a number of key elements into the Organigram stable. Sanity Group has developed a commercial footprint spanning medical cannabis, regulated recreational pilot programmes, and wellbeing products, with operations extending beyond Germany into Switzerland, the UK, Poland, and Czechia.
Its distribution and logistics capabilities, regulatory expertise, and partner network across Europe represent years of ground-level market building that would be not only costly but especially time-consuming to replicate organically.
For Organigram, which has until now been primarily a Canadian cultivator with international ambitions rather than international operations, the acquisition is genuinely transformational in scope. Sanity’s former Managing Director and Chief Investment and Strategy Officer, Max Konrad Narr, has been appointed to Organigram’s board for the duration of the earnout period.
April 15 was a striking day for the sector. Aurora® closed the Safari acquisition, Tilray announced the Lyphe deal, and Organigram completed one of the largest cannabis acquisitions in European history, all on the same date. The coincidence underscores just how compressed the current window of consolidation activity has become, with multiple operators evidently concluding simultaneously that the time to move is now.
The post Has Rescheduling Accelerated the Cannabis M&A Wave? appeared first on Business of Cannabis.
Continue reading...
